CLINICAL_TRIALS
trial_result
· 2019-04-08
Clinical Trial Update: CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients [Phase 2]
Summary
Phase 2 clinical trial update for CD19 hsCAR-T therapy in refractory/relapsed CD19+ B-ALL.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Xuanwu Hospital, Beijing | Conditions: Acute Lymphoblastic Leukemia | Phase 2 | Status: UNKNOWN